Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Neurosterix pulls in $105M for schizophrenia drug, taps Cobenfy vets

Neurosterix, which is reuniting some key figures behind Cobenfy, has corralled $105 million in a Series B to fund its lead schizophrenia candidate that hits one of the targets of Bristol Myers Squibb’s drug. The ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Wednesday 11 November →